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Interleukin-1-induced cyclooxygenase 2 expression Is suppressed by
cyclosporin A In rat mesangial cells. The immunosuppressive drug
cyclosporin A (CsA) has considerable nephrotoxic side effects which
seem to be related to its interference with the synthesis of vasoactive
prostanoids. Therefore, the molecular mechanism of the effect of CsA
on the synthesis of prostaglandin E2 (PGE2) was investigated in rat renal
mesangial cells (RMC). CsA effectively inhibited the PGE2 synthesis
induced by inflammatory cytokines such as interleukin I (IL-I) or tumor
necrosis a (TNFa). The induction by IL-i and the inhibition by CsA
were reflected in the enzyme activity of the cyclooxygenase. The
changes in activity could be correlated with the expression of the
inducible cyclooxygenase isoform (COX2), which is characterized by
its 4.4kb mRNA: the expression of this enzyme was enhanced by IL-i
and suppressed by CsA on the mRNA and protein level as determined
by Northern and Western blot analyses. Suppression of COX2 mRNA
was also observed when the message was induced by LPS or ionophore
A23187. The expression of the basal cyclooxygenase isoform (COXI),
which was constitutively expressed in proliferating mesangial cells, was
not affected by IL-i or CsA. Interferon y, which did not induce
prostaglandin synthesis or influence COX mRNA expression, aug-
mented the expression of MHC antigens in RMC. This induction was
insensitive to CsA treatment. We could thus show that the inducible
cyclooxygenase isoform in mesangial cells is a molecular target for CsA
providing a possible mechanism for the interference of the drug with the
balance of vasoactive prostanoids.
The prolonged use of cyclosporin A (CsA), necessary to
achieve adequate immunosuppression, is limited by the drug's
considerable side effects on kidney structure and function [1].
The reason for this nephrotoxicity is not yet fully understood,
although many reports dealt with the effects of CsA on renal
function and on renal cells both in vivo and in vitro [2].
The earliest changes observed after administration of the
drug were an increase in vascular resistance, accompanied by a
decrease in renal blood flow and glomerular filtration rate [3, 4].
These early changes were reversible after withdrawal of CsA
[5]. However, following long-term treatment, chronic glomeru-
lar injury occurred, resulting in persistent hypoflitration, expan-
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sion of the mesangium and increasingly elevated renal vascular
resistance [6].
The regulation of these parameters takes place in the glomer-
ulus. The cell types actively involved are the smooth muscle
cells lining the vessels and the resident glomerular mesangial
cells (MC). Both cell types are capable of contracting upon
stimulation with vasoactive substances. The intracapillary lo-
cation of the glomerular MC and their responsiveness to many
stimuli resulting in contraction or release of vasoactive media-
tors, strongly suggest that the MC is one of the central effector
cell types regulating glomerular blood flow and filtration rate.
MC have been shown to be target cells of CsA effects. We
reported that CsA potently suppressed MC proliferation in
culture in concentration ranges paralleling the antiproliferative
effect on mitogen-activated T-lymphocytes [7]. Other parame-
ters of MC behavior are affected by CsA including augmenta-
tion of calcium influx after stimulation [8—10], and reduction in
planar cell surface area [11]. Furthermore, CsA directly influ-
enced arachidonic acid metabolism in mesangial cells. The
eicosanoids, a group of potent vasoactive substances, exert
different functions on renal blood flow. Thus, PGE2 and pros-
tacyclin have vasodilatory properties, while PGF2,, and throm-
boxane mediate vasoconstriction. MC in culture were induced
to release these prostanoids by a variety of mediators, the most
potent known being proinflammatory cytokines like interleu-
kin-i (IL-l) [12], tumor necrosis factor a (TNFa) [13], or the
combination of IL-i and TNFa [141. The primary source of
these cytokines in the glomerulus are infiltrating cells of the
immune system such as monocytes, the number of which is
enhanced during infections and inflammatory reactions. The
IL-i and TNFa-induced PGE2 release was reported to be
dependent on de novo protein synthesis which could be inhib-
ited by actinomycin or cycloheximide and attenuated by CsA
[15]. Inhibition of PGE2 synthesis by CsA in MC was also
shown following stimulation with vasopressin, the calcium
ionopbore A 23187 or angiotensin II [16—18]. The molecular
mechanism underlying the observed inhibition, however, has
not yet been elucidated.
Recently, Coyne et al [19] demonstrated an increase in
cyclooxygenase (COX) activity and protein mass upon treat-
ment of MC with either IL-i or TNFa. COX protein was long
considered to be a single gene product. During the last two
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years, however, a second isozyme (COX2) was characterized in
various cell types, which is distinct in structure and functional
regulation from the "classical" COX (COX1) [20]. The contri-
bution of these two isozymes to the cytokine-induced increase
in prostanoid formation and the inhibition by CsA were inves-
tigated in the study presented.
Here, we demonstrate that IL-i potently and rapidly induced
COX2 mRNA and protein synthesis resulting in an increased
PGE2 release, but had no effect on COX1 expression. CsA
specifically supressed the IL-i-induced increase of COX2
mRNA and protein levels, but CsA had no effect on basal COX1
expression. The inhibition was not due to a general inhibitory
effect of CsA on de novo synthesized and expressed proteins,
because the enhanced expression of antigens of the major
histocompatibility complex (MHC) was not impaired by CsA.
Methods
Materials
Recombinant human interleukin-la (IL-la, spec. act. 2 x i0
U/mg) and recombinant human interleukin-1f3 (IL-ifl, spec. act.
4 x i0 U/mg) were provided by J.-M. Dayer, Geneva, Swit-
zerland. Recombinant human tumor necrosis factor alpha
(TNFa, spec. act. 8 x 106 U/mg) was from BASF/Knoll,
Ludwigshafen, Germany. Interferon gamma (IFN7, spec. act. 4
x 106 U/mg) was provided by H. Schellekens, TNO Primate
Research Center, Rijswijk, The Netherlands.
Cyclosponn A (CsA) was provided by SANDOZ AG, Basel,
Switzerland. It was dissolved in dimethylsulfoxide (DMSO) to a
concentration of 2 mg/ml and kept as a stock solution at —20°C
in the dark. Dilutions were made in culture medium containing
FCS. Solvent concentration never exceeded 0.1% DMSO (you
vol).
Mesangial cell cultures
Rat mesangial cells (RMC) were prepared from male Spra-
gue-Dawley rats as described earlier [7]. For this set of exper-
iments an established rat mesangial cell line was used (RMC
85/4) [7]. RMC were cultured in DMEM, supplemented with 5%
FCS, 2 mri L-glutamine, 100 U/ml penicillin and 100 pg/ml
streptomycin, at 37°C in a humidified atmosphere of 5% C02:
95% air.
Standard assay for prostaglandin E2 (PGE2) measurements
Routinely RMC were passaged from 80 cm2 culture flasks
into 24 well plates (NUNC, Wiesbaden, Germany) at a cell
density of 50,000 cells/well in complete culture medium. MC
were allowed to adhere for at least 24 hours and cells were used
after reaching confluency. Conditioned medium was removed
from the wells and fresh culture medium was added together
with CsA, the solvent alone (DMSO), cytokines or combina-
tions thereof. MC were incubated for the times indicated, then
conditioned media were removed and immediately tested for
PGE2 by ELISA or deep-frozen at —20°C. For protein deter-
mination, the cells were washed three times with PBS and were
dissolved in 0.1 N NaOH. A micro-Bradford assay was per-
formed with bovine serum albumin as standard [211. The PGE2
concentration in the conditioned media of the cells was as-
sessed by an ELISA technique using a monoclonal anti-PGE2-
antibody provided by Drs. Brune and Reincke, Erlangen,
Germany [22]. The method was adopted by V. Kaever, Han-
foyer, Germany. The detection limit of this ELISA is 5 pg/ml.
The cross reactivity of the antibody under these assay condi-
tions is less than 0.5% for other prostanoids or arachidonic acid.
Determination of cyclooxygenase/PGE2 isomerase activity
RMC were cultured in 80 cm2 culture flasks to confluency.
Medium was removed from the flasks and cells were given fresh
culture medium plus solvent, CsA, IL-l or combinations
thereof in a total volume of 10 ml. After 12 hours the culture
medium was removed and tested for PGE2 content. MC were
washed twice with ice cold PBS and the cells were scraped off
using a rubber policeman. The cells were disrupted by sonica-
tion in PBS. Microsomal membranes were obtained by differ-
ential centnfugation for 20 minutes at 6500 g and 60 minutes at
100,000 g. Protein concentration was determined by a microtiter
Bradford assay with bovine serum albumin as standard [21].
The synthesis of PGE2 from arachidonic acid in the mem-
brane fraction was determined as described previously [23].
Microsomal membranes were incubated with i0 M arachi-
donic acid for 30 minutes. The specific activity was calculated
as pg PGE2 x mg protein1 x min. Control assays were
performed in the presence of diclofenac, a specific inhibitor of
the cyclooxygenase.
Western blot analysis
Microsomes were prepared as described above. Electro-
phoresis (5 to 15 zg protein per lane) was carried out according
to Laemmli [24]. Proteins were transblotted onto Immobion-P
(Millipore, Bedford, Massachusetts, USA) in a buffer contain-
ing 7.8 mrt TRIS, 60 mitt glycine and 20% methanol (vol/vol),
pH 8.3 for three hours with 0.2 mA in a LKB chamber, cooled
to 0°C. The membrane was placed into saturation buffer for one
day at 4°C to block the nonspecific protein binding sites in the
membrane (saturation buffer: 100 ifiM TRIS, 0.9% NaC1 (wti
vol), 0.02% NaN3 (wt/vol), 5% low fat dry milk (wt/vol), pH
7.4).
The antibody recognizing COX1 isoform was obtained from
rabbits immunized with a ram seminal vesicle cyclooxygenase
preparation. The antibody recognizing COX2 isoform was
directed against a COX2 specific peptide [25]. The Immobilon
membrane was incubated overnight with the antisera at room
temperature in a shaking water bath. After washing with PBS,
the membrane was incubated with the second antibody for one
hour at room temperature (donkey-anti-rabbit-IgG biotinylated-
antibody; Amersham-Buchler, Braunschweig, Germany; final
dilution of 1:2000 in a freshly prepared 1% gelatin solution in
water). After washing again with PBS, 1:2000 diluted strepta-
vidin-biotinylated horseradish peroxidase complex (Amersham-
Buchler) was allowed to bind to the biotin of the second
antibody for 90 minutes at room temperature. Color develop-
ment was achieved after a further wash with PBS by adding 0.15
mg/ml 4-chloro-i-napthol (Sigma, Deisenhofen, Germany) in 50
mM sodium acetate buffer, pH 5.0, with 0.005% H202 (vol/vol).
The color developed in about five minutes. Membranes were
washed with water to stop the color reaction.
Northern blot analysis
Total cellular RNA was prepared by the guanidine isothiocy-
anate technique essentially as described by Chomczynski and
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Sacchi [26]. Northern blot analysis of total cellular RNA (10 sg)
was performed as described by the manufacturer (Boehringer
Mannheim, Germany) using a 2.7 kb COX1 cDNA from mouse
labeled with digoxigenin by in vitro transcription. The 1.1 kb
Eco RI fragment from the 5' end of the mouse COX2 cDNA was
labeled with P-32 by random priming. Northern blots were
performed as previously described [27]. An 0.24 to 9.5 kb RNA
ladder (Gibco BRL) was used for size determination of the
COX1 and COX2 transcripts. In control experiments the blots
were hybridized with a rat cDNA probe for GAPDH, obtained
by RT-PCR. For quantitative evaluation the blots were scanned
and the densitometric values corrected for GAPDH intensities
by calculating the ratio of the respective signals. Mean values
SD were determined from independent preparations.
Analysis of MHC antigen expression
RMC were incubated for 72 hours in the presence of 0.1%
DMSO, 2 pg/mI CsA, 100 U/mI TNFa plus 100 U/mI IFN'y or 2
pg/mi CsA plus cytokines. Thereafter, the cells were washed
and brought into single cell suspension by treatment with 1 mr'i
EGTA for 20 minutes at 37°C. Staining for FACS analysis was
performed by incubating the cells with the antibodies OX-18,
directed against MHC class I antigens and OX-4, directed
against MHC class II antigens (Serotec, Bicester, UK), or an
isotyped machted irrelevant antibody at 4°C for 30 minutes.
Mter washing, the labeling of the primary antibodies was
performed in a second step with an FITC-conjugated goat
F(ab')2-anti-mouse IgG reagent (Medac, Hamburg, Germany).
Relative fluorescence intensities were analyzed by flow cytom-
etry [28].
Results
Effect of CsA on cytokine-induced PGE2 release
The cytokines IL-lf3 and TNFa induced PGE2 synthesis in
RMCs in a concentration dependent manner. Data obtained
after 24 hours of incubation are depicted in Figure 1. Similar
results were also obtained with IL-la. TNFa enhanced PGE2
release to a lesser extent than IL-i. Both, IL-la and IL-1/3,
induced more than ten times the amount of PGE2 in 24 hours
compared to TNFa on a units per ml basis. Therefore, IL-1f3
was used in all subsequent experiments as stimulus of PGE2
synthesis. IFNy, a T-lymphokine, had no stimulatory effect on
PGE2 synthesis.
The cytokine-induced PGE2 release was inhibited by CsA.
The inhibition was apparent at low concentrations of 250 ng
CsAJml and was more pronounced at higher concentrations of
500 to 2000 ng CsA/ml (Table 1). Only partial inhibition of PGE2
synthesis was observed at all concentrations of IL-l/3 tested, as
even very high concentrations of CsA (2 pg/ml CsA) did not
suppress PGE2 production to basal levels (Fig. ic). Preincuba-
tion with CsA for up to four hours before addition of IL-1/3 did
not augment the inhibitory effect nn PGE2 levels compared with
the simultaneous addition of CsA and IL-lp (data not shown).
DMSO had no effect on basal or cytokine-induced PGE2
release. Time course experiments showed an early onset of
IL-1/3-induced release of PGE2 (Fig. 2). Inhibition by CsA was
clearly detectable after four hours of incubation, but became
more pronounced after longer incubation times due to the
cumulative measurement of PGE2 release.
Log concentration IL-i , U/mi
Fig. 1. Inhibition of cytokine-induced PGE2 synthesis by CsA, RMC
were incubated with or without IL-1/3 and TNFa in the presence of CsA
as indicated. After 24 hours, total PGE2 in the supernatants was
determined by a specific ELISA. Data are from one of three experi-
ments, which all gave qualitatively identical results. Symbols are: (A)
(0) control, (•) 25 pg/mI IL-l13, (0) 250 pg/ml IL-1/3, (Li) 1250 pg/mI
IL-l; (B) (0) control, (•) 500 pg/mI TNFa, (A) 5000 pg/mI TNFa; (C)
(is) control, (A) 2 pg/mI CsA, IL-l: 1 U = 25 pg.
Basal and IL-1f3-induced PGE2 release were inhibited by the
continuous presence of CsA over a prolonged period of time.
Continuous release of PGE2 into the culture medium was
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Fig. 2. Time course of PGE2 synthesis. RMC were incubated with
IL-1/3 (5 ng/ml) in the absence (Lx) or presence (A) of CsA (1 gIml).
PGE2 was determined in the culture supernatants by a specific ELISA.
Data are means of 2 independent preparations.
observed also between 24 and 48 hours of culture. A single
administration of CsA together with IL-13 was sufficient to
sustain inhibition at the level reached after 24 hours (data not
shown).
Effect of CsA on COX activity
COX activity was determined in membranes derived from
RMC by differential centrifugation. The conversion of arachi-
donic acid to PGE2 was taken as a measure of the COX enzyme
activity. The specificity of each assay was assessed in the
presence of the cyclooxygenase inhibitor diclofenac. Nonspe-
cific transformation of arachidonic acid into immunodetectable
compounds was always below 10% compared to enzymatic
conversion.
IL-lp induced COX activity in a concentration dependent
manner (Fig. 3). Inhibition of the enzyme activity in membranes
derived from cells treated with IL-1f3 plus CsA (1 jxg/ml) was
comparable to the inhibition of PGE2 release [500 pg/mI IL-l3:
48 18% inhibition (means SD, N = 4), 5000 pg/mI IL-1/3: 52
17% inhibition (N = 3)]. There was no significant effect of
CsA treatment of the cells on the basal COX activity (110
14% compared to control, N = 4).
Effect of IL-Ip and GsA on COXI and COX2 mRNA
expression
To further elucidate the molecular mechanisms of the induc-
tion of COX activity, COX mRNA expression was measured by
II
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Fig. 3. Effect of IL-I 13 and CsA on COX activity. COX activity was
determined in microsomes prepared from RMC treated overnight with
IL-l/3 (0.5 or 5 rig/mI) and CsA (1 pg/mI) as indicated. CsA*: CsA was
added to niicrosomes from control cells during the incubation with
arachidonic acid. Data are means of triplicates of a typical example.
Northern blot analysis. Under basal conditions, a distinct signal
was obtained with a probe directed against COX1 isozyme,
while COX2 mRNA was barely detectable. The size of the
COX1 mRNA was about 3.4 kb in these rat cells and differed
significantly from the size of the COX1 detected in human
monocytic cells (2.8 kb) with the same cDNA probe [29]. Upon
incubation with IL-1p, the expression of COX1 mRNA re-
mained unaltered (Figs. 4 and 5). To correlate changes in PGEZ
production seen in earlier 24 hour incubations (Fig. 1) we
measured COX2 mRNA levels after an overnight incubation
following addition of IL-1/3. At this time, COX2 mRNA was
strongly induced by IL-1J3, while no change was observed in the
expression of COX1 mRNA (Fig. 4). CsA had no effect on the
constitutive expression of COX1 mRNA in RMCs, but the
induction of COX2 mRNA by IL-1J3 was reduced (Fig. 4).
Subsequent experiments on the time course of mRNA induction
showed that COX2 mRNA was markedly induced within four
hours of addition of IL-1/3 (Fig. 5). Compared to the low levels
seen in control RMC, COX2 mRNA was enhanced sixfold
(Table 2). The induction was long lasting, a fourfold induction
was still seen after 12 hours (4.25 0.45, means range, N
2). In the presence of CsA, COX2 mRNA expression remained
at lower levels. Mter four hours, induction was only 2.9-fold,
corresponding to a 50% inhibition by CsA (Table 2).
A comparable induction of COX2 mRNA was also obtained
by incubation of mesangial cells with LPS (100 ng/ml) or the
Ca2 ionophore A 23187(1 g/ml). As seen with IL-1/3, CsA did
not prevent the induction of COX2 mRNA completely, but
impaired the induction to approximately the same extent (Table
2). IFNy had no effect on either COX1 or COX2 mRNA
expression (data not shown).
Effects of IL -1 13 and CsA on protein synthesis of COXI and
COX2
The effects of IL- 1f3 and CsA on the 1TIRNA expression of the
COX isozymes were also reflected in the modulation of protein
mass as determined by Western blot analysis. Cells were
Table 1. Percent inhibition of IL-i-induced PGE2 release 250
200
150
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50
E
I
RMC were incubated with 250 pg/ml IL-i and CsA as indicated. Total
PGE2 in the supernatant of IL-l-stimulated cells was taken as 100%.
Data are means SD of 4 independent experiments.
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incubated with IL-1f3 overnight and subsequently crude mi-
crosomes were prepared. The antibody against COX1 recog-
nized two bands of molecular weights of about 74 kDa and 67
kDa (Fig. 6). There was no significant effect of IL-1/3 or CsA,
respectively, on COX1 protein expression. The COX2 antibody
recognized one protein band of about 74 kDa. It was barely
detectable in control cells and strongly induced by incubation of
RMC with IL-1$. In microsomes obtained from IL-1/3-stimu-
lated RMC treated with CsA COX2 protein was found to be
reduced by 55% (N = 2) in accordance with the data obtained
by Northern blot analysis.
Effect of cytokines and GsA on MHC antigen expression
RMC in culture express MHC I antigens but not MHC II
antigens on the surface. This basal expression was not affected
by CsA (Fig. 7). Previously, we showed that TNFa and IFN7
enhanced MHC class I antigen and induced MHC class II
antigen expression in RMC as determined by FACS analysis
[281. This was confirmed in the present experiments, using
optimal concentrations of TNFa (100 U/ml) and IFNy (100
UIml). Even very high concentrations of CsA (2 pg/m1) had no
influence on the cytokine-induced expression of MHC antigens.
Discussion
An increasing number of reports demonstrate direct and
specific effects of CsA on renal cells, which suggest that
immunosuppressive activities, for example, in autoimmune
disorders or graft rejection, as well as nephrotoxic phenomena
may be due to the interference of the drug with intrinsic
regulatory mechanisms within the kidney. One of the cell types
pivotal to maintenance and regulation of the glomerular ultra-
filtration apparatus is the glomerular mesangial cell. MC pro-
duce considerable amounts of vasoactive mediators upon
stimulation with substances ranging from bacterial lipopolysac-
charides, components of the complement system or angiotensin
II to cytokines such as IL-i or TNFa. Thus MC are not only
target cells for vasoactive substances thought to be responsible
for the modulation of glomerular blood flow, but they are also
effector cells, which can release mainly PGE2, a vasodilatory
eicosanoid and potent negative regulator of the immune re-
sponse [30—32]. MC may also be involved in the local immune
response in a variety of renal disorders.
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FIg. 4. Effect of CsA and IL-I/3 on COX
mRNA expression. RMC were incubated
overnight with or without IL-l/3 (5 ng/mI) or
CsA (1 tg/ml). Northern blot analysis was
performed as described in Methods. The blot
is representative for three similar ones.
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Fig. 5. Time course of COX mRNA expression in the presence or
absence of CsA. RMC were incubated with IL-1/3 (5 ng/ml) with CsA
(hatched bars) or without CsA (1 g/ml) (open bars) for the times
indicated. Northern blot analysis was performed and the blot hybrid-
ized with eDNAs specific for COXI, COX2 and GAPDH. Abbreviation
is Co, proliferating cells without IL-ip or CsA. Data shown are relative
densitometric values with GAPDH as reference signal.
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Table 2. Regulation of COX2 mRNA in RMC
Stimulation of COX2
mRNA expression
Inhibition by CsA
%
IL-l/35ng/ml 6.4±0.7 53±9
LPS 100 ng/ml 9.5 2.1 67 7
A 23 187 1 rsg/ml 4.7 0.2 40 10
RMC were incubated with the stimuli indicated for 4 hours in the
absence or presence of CsA (1 g/ml). COX2 mRNA was detected by
Northern blot analysis. To confirm equal quantities of RNA, all blots
were hybridized with a cDNA probe for GAPDH. Densitometric values
of COX2 mRNA were corrected for GAPDH signals. Stimulation was
calculated as fold increase compared to nontreated RMC. Data are
means SD (N = 3, stimulus IL-1/3) or means range (N = 2, stimuli
LPS or A 23187).
Cell culture approaches have enabled us and others to study
the effects of drugs on the behavior of glomerular cells in clearly
defined in vitro systems. CsA effectively inhibited the vasocon-
strictor-induced POE2 synthesis in mesangial cells [1], thus
interfering with the balance of vasoconstrictor and vasodilator
influences. Now, we could show that CsA also interfered with
the cytokine-induced release of the main arachidonate metabo-
lite of MC in culture, PGE2. IL-i was chosen to induce
prostaglandin synthesis, because it is a central mediator of
inflammatory processes and has also been shown to be involved
in the pathogenicity of renal disorders [33]. All experiments
were performed with cycling cells, that is, in the presence of
FCS, as in inflammatory situations mesangial cells frequently
proliferate.
IL-I and TNFa enhanced the basal prostaglandin formation
in a concentration dependent manner. CsA reduced the en-
hanced PGE2 release of RMC by about 50%. In none of the
experiments did CsA inhibit IL-i or TNFa-induced POE2
release to control levels, even if the drug was given for 72
hours. These observations suggest a molecular mechanism not
only different from the direct COX inhibition by nonsteroidal
anti-inflammatory drugs (such as acetylsalicylic acid), but also
different from the receptor-mediated effect of glucocorticoids,
which reduce cytokine-induced POE2 synthesis to backgrounds
levels [19]. Suppression of PGE2 synthesis was observed at
early time points of stinftilation by IL-i, that is, as early as four
to six hours after onset of stimulation, and also during the
prolonged release of POE2 between 24 and 48 hours of incuba-
tion. This time course suggested a pronounced inhibitory effect
on the molecular mechanisms underlying induction of PGE2
synthesis, not just an attenuating effect of CsA on the existing
enzymatic machinery.
Previous experiments studying antiproliferative effects of
CsA on rat MC in culture [7] have shown that 125 to 250 ng/ml
CsA yielded detectable suppression of thymidine incorporation,
which was reversible after withdrawal of the drug. The same
concentration range of CsA inhibited IL-i-induced PGE2 re-
lease when added simultaneously with the cytokine, but higher
concentrations (500 to 1000 ng/ml) were necessary to obtain
pronounced effects. This is in accordance with other studies
with RMC [17]. The concentrations of CsA used were relatively
high when compared to the amount required for effective
inhibition of T-lymphocyte proliferation (100 ng/ml) and ex-
ceeded conventional therapeutic levels in humans. However, as
discussed by Stahl et al [17] and by us [7], tissue levels in the
kidney may be considerably higher than CsA levels determined
in serum. Furthermore, the threshold for nephrotoxicity seems
to be higher in rats than in humans. Therefore, the concentra-
tions used in this study are likely to be within the concentration
range which leads to nephrotoxicity in vivo.
The mechanism by which CsA interferes with POE2 synthesis
has been discussed at different levels. The inhibitory effect of
CsA on phorbol ester-stimulated POE2 release of RMC was
discussed as direct interference of the lipophilic substance CsA
with the activation process of the protein kinase C [34]. The
formation and release of prostanoids from mesangial cells is a
multi-step process requiring a series of enzymatic conversions
of the educt arachidonic acid to the final product, in this study,
POE2. Arachidonic acid is liberated upon stimulation from
plasma membrane phospholipids. Pfeilschifter et al [15] showed
in RMC that phospholipase A2 activity is enhanced by IL-1/3
and TNFa treatment. In those studies CsA inhibited the cyto-
kine-induced phospholipase A2 synthesis and release. Stahl et
al [17] reported that CsA inhibited the release of radiolabeled
arachidonate in RMC after stimulation with the calcium iono-
phore A23 187 or angiotensin II. No effect of CsA was observed
on the activity of the microsomal cyclooxygenase. Similar
results were also obtained by Skorecki, Rutledge and Schrier
[35] using vasopressin-stimulated MC, indicating an effect of
CsA at the level of arachidonic acid liberation.
In our studies, we focused on the second step of the arachi-
donate cascade. Cyclooxygenase (prostaglandin 0/H synthase,
COX) utilizes arachidonic acid as a substrate to produce a
metastable intermediate product, which is then further pro-
cessed to different prostanoids, depending on the enzymatic
equipment of the respective cell type. Recently, it was shown
that IL-i/3 and TNFa induced de novo synthesis of COX
molecules in mesangial cells [19]. This was paralleled by an
enhancement of POE2 release into the conditioned media of
these cultures and an increased enzymatic activity measured in
microsomes obtained from IL-113 or TNFa-treated MC.
Here we demonstrate that COX activities were reduced in
microsomes obtained from IL-113 plus CsA-stimulated RMC. In
accordance with the data of Stahl et al [17], we could not detect
any effects on COX activity in RMC microsomes, when the
microsomes were incubated with CsA. This indicated an effect
of CsA on COX biosynthesis, which was confirmed on protein
and mRNA level.
The two isoforms of COX presently known are regulated in a
cell type and stimulus specific manner [20]. IL-i/3 was shown to
induce COXI mRNA in human endothelial cells and COX2
mRNA in human monocytes [36, 37]. Now we showed that in
RMC IL-1,3 had no significant effect on COX! expression but
strongly induced COX2 mRNA and protein, which were barely
detectable in nonstimulated proliferating cells. These data are in
accordance with those of Coyne et a! [19], assuming that the
antibody used by this group might cross react with both, COX1
and COX2. A maximal COX2 mRNA signal was obtained after
four hours of incubation with IL-l)3. Thereafter, COX2 mRNA
levels slowly declined, but remained elevated for more than 20
hours.
CsA interfered at the mRNA level with the induction of
COX2 without effecting the constitutive expression of COX1.
The effect of CsA was not restricted to the IL-1f3-induced
COX2 mRNA expression. It was previously shown that LPS
— —
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Fig. 6. Effect of GsA and IL-i f3 on COX
protein expression. RMC were incubated
overnight with or without IL-113 (5 ng/ml) or
CsA (1 pg/mI). Western blot analysis was
performed as described in Methods.
Abbreviations are St, molecular weight
standard; Ko, control. The blot is
representative of three independent
experiments.
transduction pathway between receptor and transcription of the
specific gene might be the target of CsA action.
The missing effect of CsA on the constitutively expressed
D COX1 isozyme explained the minor effects of CsA on basal
POE2 release. Other mechanisms such as an effect on phospho-
lipase A2 may also contribute to the marginal reduction in basal
PGE2 release. The striking concurrence of CsA-mediated inhi-
GSA bition of POE2 release, COX activity and COX2 protein and
mRNA expression strongly suggests that the interference of
CsA at this step of the biosynthetic cascade is the most
TNF relevant, which, however, does not exclude effects of CsA at
+ other levels. The interference of CsA with the induction of
IFN prostaglandin synthesis was specific, as other induction path-
ways in RMC were not effected. As an example, we measured
GsA the induction of MHC class I and class II antigens by IFN7 and
+ TNFa. CsA had no effect on the basal or induced expression of
INF these antigens.
PFN The interference with an induction pathway resulting in
inhibition of mRNA expression and of de novo protein synthe-
sis of specific proteins, while leaving others unaffected, resem-
bles the action of CsA on mitogen activated T-lymphocytes. In
this system CsA blocked completely the production of the
autocrine growth factor IL-2 by activated T cells, while other
proteins were still produced [38].
It is thus tempting to speculate that the mechanisms of CsA
action on a molecular level may be very similar in MC and T
cells. On the contrary, cell specific regulation by CsA has
recently been demonstrated with respect to the expression of
phosphoenolpyruvate carboxykinase, which was inhibited by
CsA in the kidney but not in the liver [391.
In summary, we demonstrate that the regulation of cytokine
induction of and CsA interference with PGE2 synthesis in
mesangial cells occurs at the level of COX2 mRNA. COX2 is
thus a new member of the group of genes whose expression is
CsA sensitive. There are multiple reports in the literature that
CsA in addition to inhibiting the synthesis of the vasodilator
32.5
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MHC II MHC I
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Fig. 7. Induction of MHC antigen expression in the presence of CsA.
RMC were incubated for 72 hours in the presence of 0.1% DMSO (D),
2 pg/mi CsA (CsA), 100 U/mI TNFa plus 100 U/mi IFN-y (TNF + IFN)
or CsA plus cytokines (CsA ÷ TNF + IFN). Expression of an
irreievant antigen (FITC) and of MHC class I or MHC class II antigens
was determined by FACS analysis. Data shown are from one experi-
ment representative of three identical ones.
and ionophore were inducers of PGE2 synthesis in RMC [17]. In
our experiments, both compounds induced the expression of
COX2 mRNA to a similar extent as IL-lp in RMC. Again, CsA
was an effective partial inhibitor of the induction.
It is unclear at present, whether the observed regulation of
COX2 mRNA in mesangial cells is due to an increase in mRNA
synthesis and or an enhanced stability of the mRNA. Further-
more, it remains to be evaluated which step of the signal
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PGE2 enhanced the synthesis of the vasoconstrictor thrombox-
ane, most likely in extrarenal cells [1]. One might speculate that
other effects of CsA, such as the enhancement of intracellular
calcium or inhibition of the reacylating system of membrane
phospholipids [40], might be essential in cells without the
capacity of de novo protein biosynthesis, such as platelets. This
would explain the adverse effects of CsA on prostanoid synthe-
sis which in summary contribute to the interference of CsA with
renal hemodynamics.
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Appendix. Abbreviations
COX, cyclooxygenase = prostaglandin endoperoxide synthase =
prostaglandin GH synthase; CsA, cyclosporin A; IL-i, interleukin 1;
POE2, prostaglandin E2; RMC, rat mesangial cells; TNFa, tumor
necrosis factor a; IFN7, interferon gamma; MHC, major histocompat-
ibiity complex.
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